Mussell M, Hewer W, Kulzer B, Bergis K, Rist F
Central Institute of Mental Health, Department of Psychiatry and Psychotherapy, University of Heidelberg, Medical Faculty of Mannheim, Theodor-Kutzer-Ufer, D-68315 Mannheim, Germany.
Diabet Med. 2004 Nov;21(11):1253-6. doi: 10.1111/j.1464-5491.2004.01322.x.
In a previous study we failed to find beneficial short-term effects of improved glycaemic control on cognitive functioning in patients with Type 2 diabetes mellitus. A subgroup of the entire sample was tested again to examine the effect of longer-lasting improvement of metabolic control on cognitive functioning.
The cognitive performance of 26 patients with Type 2 diabetes was assessed at baseline and 3 months after discharge. Thirteen controls were tested at the similar time-points. Attention/concentration, psychomotor speed, verbal fluency, verbal memory and depressive symptoms were assessed. Improved glycaemic control was generally achieved with insulin therapy (20/26).
At baseline, there was a trend for diabetic patients to perform worse than controls. Both groups improved significantly over 3 months in several measures. However, diabetic patients did not improve more than controls.
In individuals with long-standing Type 2 diabetes, previous reports of improved cognitive capacity following restoration and maintenance of near-normoglycaemia were not confirmed. This might relate to the type of anti-diabetic therapy.